Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

N/A

1(12.5%)

8Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06469411Phase 3Completed

Effect of PMSCs and Their Secretome for the Treatment of GvHD

Role: collaborator

NCT03227198Phase 1Unknown

IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients

Role: lead

NCT03183973Phase 1Unknown

Effects of Platelet Rich Fibrin (PRF) in Treatment of Non-healing Sternum Wound After Open-heart Surgery

Role: lead

NCT03140319Phase 1Unknown

Transplantation of Fibroblast for Correction of Nasolabial Folds

Role: lead

NCT03164083Phase 2Withdrawn

The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis

Role: lead

NCT03162367Phase 2Completed

Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn

Role: lead

NCT03145402Phase 1Unknown

ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients

Role: lead

NCT03267797Not ApplicableCompleted

hCG-activated PBMC-therapy in RIF Patients

Role: lead

All 8 trials loaded